Evidence map›Paper›PMID 40721291›Full record

ArticleLife science alliance2025

Enforced MYC expression directs a distinct transcriptional state during plasma cell differentiation.

Panagiota Vardaka, Ben Kemp, Sophie Stephenson, Eden Page, Matthew A Care, Michelle Umpierrez, Adam Annahar, Eleanor O'Callaghan, Roger Owen, Daniel J Hodson and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Panagiota VardakaDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.ORCID 0000-0002-1253-243X
Ben KempDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.ORCID 0009-0008-3927-6414
Sophie StephensonDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Eden PageDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.ORCID 0000-0001-6340-9872
Matthew A CareEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Michelle UmpierrezDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.ORCID 0000-0002-0121-820X
Adam AnnaharDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.ORCID 0000-0002-2298-8641
Eleanor O'CallaghanDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.ORCID 0009-0003-1363-183X
Roger OwenHaematological Malignancy Diagnostic Service, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Daniel J HodsonWelcome MRC Cambridge Stem Cell Institute, Cambridge, UK.ORCID 0000-0001-6225-2033
Gina M DoodyDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
Reuben M ToozeDivision of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, Leeds, UK r.tooze@leeds.ac.uk.ORCID 0000-0003-2915-7119

Funding

Blood Cancer UK Project Grant 23021Cancer Research UK (CRUK) RCCFEL∖100072Cancer Research UK - FC AECC / AIRC under the Accelerator Award Program C355/A26819Cancer Research UK Programme Grant C7845/A29212National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (BRC) NIHR203331Wellcome Trust
6 · The paper itself

Abstract

MYC provides a rheostat linking cell growth and division. Deregulation of MYC drives transformation in aggressive B-cell neoplasms, often accompanied by BCL2-mediated apoptotic protection. We assess how MYC and BCL2 deregulation impacts on the ability of human B cells to complete plasma cell (PC) differentiation. As B cells differentiate, MYC deregulation has little impact on the regulatory circuitry controlling B-cell identity. Induction of transcriptional regulators BLIMP1 and IRF4 remains intact and accompanies loss of B-cell surface markers. However, such differentiating cells develop an aberrant surface phenotype with reduced expression of phenotypic markers of differentiation. Although functional antibody secretion is established, enforced MYC expression dampens the expression of secretory programmes associated with PC differentiation. Accompanying this, diverse changes in the expression of genes related to translation and metabolism are observed. The establishment of this aberrant differentiated state depends on MYC homology box II. This dependence is profound and resolves to residue W135.

Indexed as

Cell DifferentiationPlasma CellsProto-Oncogene Proteins c-mycB-LymphocytesGene Expression RegulationHumansInterferon Regulatory Factor-4Interferon Regulatory FactorsPositive Regulatory Domain I-Binding Factor 1Proto-Oncogene Proteins c-bcl-2Transcription, GeneticBCL2 protein, humanInterferon Regulatory Factor-4Interferon Regulatory FactorsMYC protein, humanPositive Regulatory Domain I-Binding Factor 1PRDM1 protein, humanProto-Oncogene Proteins c-bcl-2Proto-Oncogene Proteins c-myc

Identifiers

PMID40721291
PMCPMC12305944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.